Yu, Xufen http://orcid.org/0000-0001-7794-7890
Wang, Jun
Gong, Weida
Ma, Anqi
Shen, Yudao
Zhang, Chengwei
Liu, Xijuan
Cai, Ling
Liu, Jing
Wang, Gang Greg http://orcid.org/0000-0002-7210-9940
Jin, Jian http://orcid.org/0000-0002-2387-3862
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01CA218600, R01CA268519, R01CA230854, R01CA218600, R01CA268519)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 3 October 2022
Revised: 25 January 2023
Accepted: 30 January 2023
First Online: 7 February 2023
Competing interests
: The Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. JJ is a cofounder and equity shareholder in Cullgen, Inc., a scientific cofounder and scientific advisory board member of Onsero Therapeutics, Inc., and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc. The other authors declare no competing interests.